Ajai Chari, Markus Munder, Katja Weisel, Matthew Jenner, Ceri Bygrave, Maria Teresa Petrucci, Mario Boccadoro, Michele Cavo, Niels W C J van de Donk, Mehmet Turgut, Fatih Demirkan, Ihsan Karadogan, Edward Libby, Robert Kleiman, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Christoph Heuck, Ming Qi, Pamela L Clemens, Hartmut Goldschmidt
INTRODUCTION: Daratumumab is a CD38-targeting monoclonal antibody that has demonstrated clinical benefit for multiple myeloma. Daratumumab inhibition of CD38, which is expressed on immune cell populations and cardiomyocytes, could potentially affect cardiac function. This QTc substudy of the phase 2 CENTAURUS study investigated the potential effect of intravenous daratumumab monotherapy on QTc prolongation and other electrocardiogram (ECG) parameters, including concentration-QTc effect modeling...
January 20, 2021: Advances in Therapy